Dr. Stefano Stuard is an internationally recognized clinical leader and researcher in hemodialysis, with a focus on advancing dialysis therapies to improve survival, reduce complications, and enhance quality of life in patients with end-stage kidney disease. His academic work centers on the evolution from conventional hemodialysis toward more physiological extracorporeal therapies, particularly high-volume post-dilution hemodiafiltration, where he has contributed significantly to defining therapeutic targets, implementation strategies, and real-world clinical impact. His research spans several interconnected domains: technological innovation in dialysis equipment, biocompatibility and membrane performance, precision fluid management, vascular access preservation, and evidence-based anemia and mineral metabolism control. He has been a pioneer in the development and validation of clinical governance frameworks—most notably Medical Patient Review programs—that link medical key performance indicators with positive patient outcomes across large care networks. Dr. Stuard has extensively published analyses leveraging large-scale registries and real-world evidence—including the European EuCliD database—to demonstrate the benefits of convective hemodialysis therapies on mortality, cardiovascular stability, inflammation, and hospitalization. His academic collaborations span Europe, the United States, Asia-Pacific, and Latin America.
Best young researcher in Europe
European Society of Artificial Organs1
1997
AKZO Nobel Reserch Award
European Society of Artificial Organs
Best young researcher in Europe in the field of biocompatibility of hemodialysis membranes
President, CEO or Director
Fresenius Medical Care (United States), Waltham, USA
01 Oct 2024 - 01 Dec 2025
President, CEO or Director
Fresenius Medical Care (Germany), Bad Homburg, Germany
01 Sep 2010 - 01 Sep 2024
Institute, Department or Faculty Head
Nephrology and Dialysis departments, L’Aquila, Italy
01 Mar 2008 - 01 Aug 2010